Development of proprietary medicines

Adamed Discovery – Where Polish Innovation Begins

At our state-of-the-art Research and Development Center in Kajetany, the multidisciplinary team at Adamed Discovery is dedicated to developing new molecules and future therapies. Leveraging advanced technologies—including cutting-edge laboratory techniques, machine learning, and artificial intelligence—our scientists are actively seeking candidates for original drugs in oncology and neuropsychiatry.

We have been at the forefront of original pharmaceutical research in Poland, establishing a robust foundation that has facilitated the development of novel molecules domestically and set the stage for continued innovation in the field. To advance these objectives, we have entered numerous partnerships with leading academic institutions and actively engaged the broader scientific community in our drug discovery initiatives.

With over 20 years of experience and expertise, our team excels in:

1. Designing and optimizing methods for obtaining both small molecules and biologics,
2. Conducting advanced analytics and structural characterization,
3. Verifying functionality and efficacy at the molecular level through cellular assays,
4. Assessing the potential of these molecules to progress through subsequent development stages by determining their pharmacokinetic and pharmacodynamic parameters, as well as their safety profiles in toxicological studies.

In our work on the development of new molecules, we use advanced mathematical tools and in silico modeling, i.e. computer simulations that allow us to predict their properties and operation. We also use machine learning and AI algorithms to help analyze data and design and improve molecules with therapeutic potential.

Currently, our activities are centered on five research programs: three oncology projects, two neuropsychiatric drug development projects, and exploratory initiatives aimed at evaluating new concepts.

Among our accomplishments, we have identified and progressed two drug candidate molecules into clinical development. The first is a recombinant fusion variant of the TRAIL/Apo2L protein, designed by our scientists as a candidate for the treatment of solid tumors. In 2025, we initiated its phase I clinical trial in Poland, in collaboration with national partners. The second molecule is a selective inhibitor of MDM2 and p53 activity and has exhibited anticancer properties in preclinical models of sarcomas, lymphomas, and leukemias. This initiative is presently underway at clinical trial centers in the United States through our collaboration with Lamassu Biotech.

Strategic partnerships and licensing agreements are integral to our drug development strategy. In the area of CNS drug research, we signed a license agreement with Acadia Pharmaceuticals in 2020. We remain actively engaged in seeking new partners for future collaborations.

adameddiscovery.com